Archive WILEX Ad-hoc- and Press Releases 2004 and before


Selected press releases of the former years can be found here.


08 October 2004
WILEX acquires option for US marketing rights to RENCAREX®*
20 September 2004
WILEX starts clinical trial with new anti-cancer compound WX-671
09 August 2004
Niels Ackermann appointed Chief Financial Officer and Member of the Executive Board of WILEX AG
15 June 2004
WILEX starts patient enrollment in RENCAREX®* pivotal Phase III trial in Renal Cell Carcinoma
25 May 2004
WILEX and Fox Chase Cancer Center begin clinical trial in the U.S. with novel compound WX-UK1 targeting tumor cell invasion and metastasis
10 May 2004
WILEX receives IND approval from FDA for Phase III trial with RENCAREX®* in Renal Cell Carcinoma
06 May 2004
Niels Ackermann to Head Finance Department at WILEX AG
26 April 2004
WILEX and Esteve sign co-development and marketing agreement for RENCAREX®* in Southern Europe
01 March 2004
WILEX’s antibody RENCAREX®* shows positive long term survival in follow-up of Phase II trial in Renal Cell Carcinoma patients
14 January 2004
WILEX starts clinical Phase I trial with anti-cancer compound WX-UK1 in head and neck cancer patients


02 December 2003
WILEX receives patents for its anti-cancer drug candidate WX-UK1 in USA, Europe and Australia
08 October 2003
WILEX awarded third prize of European BioTechnica Award for Excellence in Biotech Business
04 September 2003
WILEX and Fox Chase Cancer Center awarded first Biotechnology Clinical Partnership Award worth $3.9 million from U.S. Department of Defense Breast Cancer Research Program
01 September 2003
Former Oxford GlycoSciences CEO and Bayer Pharmaceutical Division President elected Chairman of WILEX’s Supervisory Board
22 May 2003
WILEX receives IND Approval from FDA for its anti-Cancer drug candidate WX-UK1
15 May 2003
WILEX licenses anti-cancer antibody from VU University Medical Center Amsterdam
6 March 2003
WILEX appoints Paul Bevan as new Head of Research and Development
17 February 2003
WILEX and the San Raffaele Biomedical Science Park develop antibodies against new tumor target


28 November 2002
Study on clinical Phase II trial with antibody cG250 against renal cell carcinoma receives Clinical Science Award 2002
20 November 2002
WILEX receives Drug Manufacturing Permission and international GLP certification from German authorities (German only)
14 October 2002
WILEX initiates first clinical trial for Urokinase Inhibitor WX-UK1 in cancer patients
09 April 2002
WILEX’s WX-G250 renal cancer therapeutic shows clinical benefit in Phase II trial
08 April 2002
WILEX receives Orphan Drug Designation in Europe for WX-G250
18 March 2002
WILEX reports positive Phase Ia clinical data on its anti-metastatic Urokinase Inhibitor WX-UK1
04 March 2002
WILEX appoints members to its Scientific Advisory Board


12 November 2001
WILEX AG and Bayer Corporation sign license, sublicense and option agreement
20 September 2001
WILEX starts Phase I trial with anti-metastatic Urokinase Inhibitor Drug
1 June 2001
WILEX’s cancer drug receives Orphan Drug Designation
18 May 2001
WILEX and LICR report results from completed Phase I trial of cG250 in renal cancer patients


13 November 2000
WILEX completes Euro 30 Million financing to advance cancer programs
22 May 2000
WILEX appoints Vice President Business Development


31 August 1999
WILEX licences antibody for renal cancer
14 April 1999
WILEX appoints Professor Sven Warnaar as Vice-President of Oncology
4 March 1999
WILEX receives DM 1.8 Million BioRegio Grant
Seite gelesen: 490 | Heute: 2